Skip to main content

Table 4 Correlations between clinicopathological features and BCOR expression in all the included cases

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

CharacteristicsAll (N = 44)BCOR   
  Negative (N = 23)Focal weak +ve (N = 7)Diffuse strong +ve (N = 14)p-value
 No. (%)No. (%)No. (%)No. (%) 
Age (years)
 Mean ± SD56.84 ±7.9362.52 ±4.9851 ±7.8550.42 ±4.23<0.001*
 Median (Range)57 (39-72)62 (56-72)51 (39-60)50 (44-60) 
 ≤ 55 years18 (40.9%)0 (0%)5 (27.8%)13 (72.2%)<0.001‡
 > 55 years26 (59.1%)23 (88.5%)2 (7.7%)1 (3.8%) 
Histopathology
 LMS22 (50%)19 (86.4%)2 (9.1%)1 (4.5%)<0.001‡
 ESS22 (50%)4 (18.2%)5 (22.7%)13 (59.1%) 
Grade
 Grade I9 (20.5%)9 (100%)0 (0%)0 (0%)<0.001‡
 Grade II12 (27.3%)6 (50%)6 (50%)0 (0%) 
 Grade III23 (52.3%)8 (34.8%)1 (4.3%)14 (60.9%) 
Extrauterine extension
 Absent6 (13.6%)6 (100%)0 (0%)0 (0%)0.007‡
 Present9 (20.5%)7 (77.8%)2 (22.2%)0 (0%) 
 N/A29 (65.9%)10 (34.5%)5 (17.2%)14 (48.3%) 
LVSI     
 Absent21 (47.7%)15 (71.4%)5 (23.8%)1 (4.8%)0.001‡
 Present23 (52.3%)8 (34.8%)2 (8.7%)13 (56.5%) 
Other pelvic organ invasion
 Absent15 (34.1%)9 (60%)5 (33.3%)1 (6.7%)0.010‡
 Present29 (65.9%)14 (48.3%)2 (6.9%)13 (44.8%) 
Adnexal invasion
 Absent11 (25%)11 (100%)0 (0%)0 (0%)0.001‡
 Present33 (75%)12 (36.4%)7 (21.2%)14 (42.4%) 
Lymph node
 Negative16 (36.4%)14 (87.5%)2 (12.5%)0 (0%)0.001‡
 Positive28 (63.6%)9 (32.1%)5 (17.9%)14 (50%) 
Distant metastasis
 Absent29 (65.9%)19 (65.5%)7 (24.1%)3 (10.3%)<0.001‡
 Present15 (34.1%)4 (26.7%)0 (0%)11 (73.3%) 
FIGO Stage
 Stage I6 (13.6%)6 (100%)0 (0%)0 (0%)<0.001‡
 Stage II10 (22.7%)8 (80%)2 (20%)0 (0%) 
 Stage III13 (29.5%)5 (38.5%)5 (38.5%)3 (23.1%) 
 Stage IV15 (34.1%)4 (26.7%)0 (0%)11 (73.3%) 
Stathmin
 Negative19 (43.2%)4 (21.1%)5 (26.3%)10 (52.6%)0.007‡
 Focal weak +ve12 (27.3%)10 (83.3%)0 (0%)2 (16.7%) 
 Diffuse strong +ve13 (29.5%)9 (69.2%)2 (15.4%)2 (15.4%) 
Transgelin
 Negative25 (56.8%)7 (28%)5 (20%)13 (52%)0.004‡
 Focal weak +ve6 (13.6%)6 (100%)0 (0%)0 (0%) 
 Diffuse strong +ve13 (29.5%)10 (76.9%)2 (15.4%)1 (7.7%) 
Cyclin-D1
 Negative24 (54.5%)21 (87.5%)2 (8.3%)1 (4.2%)<0.001‡
 Focal weak +ve5 (11.4%)2 (40%)3 (60%)0 (0%) 
 Diffuse strong +ve15 (34.1%)0 (0%)2 (13.3%)13 (86.7%) 
  1. * Kruskal Wallis H test; ‡ Chi-square test; p < 0.05 is significant